What is CRSP's current stock price?

As of now, CRSP is trading at $53.07, with a daily change of +8.46%.

What are the risks associated with CRSP stock?

CRSP has Fair, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

CRSP

CRISPR Therapeutics

$53.07

+$4.14 | +8.46%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$78.48

MKT CAP

$5.10B

52W Low

$30.06

VOL

$2.46M

P/E Ratio

N/A

AVG VOL

$1.77M

RSI

52.17

TREND

Sideways

CRSP Stock IQ

Login to see CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CRSP Target Price

Login to display

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Trading below its fair value

CRSP Rewards

Outperform the market

CRSP Price Performance

$52.61 (+0.87%)

$50.77 (+4.53%)

$60.76 (-12.66%)

$43.45 (+22.14%)

1year

6month

3month

1month

CRSP Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is negative and it remained unchanged from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

CRSP Street Sentiment

CRSP Street Sentiment is bullish and have positive views on the near-term outlook

CRSP Risk Level

CRSP has Fair risk level

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

CRSP Performance Sentiment

Sentiments overview associated with events and the stock performance

72%

28%

Positive

Negative

13 out of 18
events present

5 out of 18
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$53.07

Resistance
Price

$45.88

Current Price Range

$60.80

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

6

0

Date

Action

Rating

Firm

Dec 31, 2025

Reiterate

Buy

Chardan

Dec 24, 2025

Reiterate

Buy

Needham

Dec 24, 2025

Reiterate

Outperform

Citizens

Nov 13, 2025

Reiterate

Buy

Citigroup

Oct 17, 2025

Reiterate

Buy

B of A Securities

CRSP Latest Analysis +

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss). Key PointsCRISPR Therapeutics&rsquo. fourth quarter was relatively disappointing.

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

CRSP Posts Wider-Than-Expected Loss in Q4 Sales Miss Estimates. CRISPR Therapeutics posts a wider Q4 loss and revenues miss but Casgevy sales climb with label expansion plans and pipeline updates ahead.

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

Earnings

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens. CRSP) on Friday reported its fourth-quarter and highlighting continued clinical progress expanding uptake of Casgevy and momentum across its gene-editing and RNA-based pipeline.Casgevy the company’.s gene-editing and transfusion-dependent beta thalassemia generated $54 million in fourth-quarter revenue and $116 million for the full year.A total of 64 patients received infusions in 2025 including 30 during th

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

CRISPR Therapeutics GAAP EPS of -$1.37 misses by $0.22 revenue of $0.86M misses by $3.16M.

Thu Feb 12, 2026

$48.93 | +1.26%

Earnings

Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline. CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30 Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that much of the pipeline remains undervalued and noted that the company could begin late-stage development for up to [….]

Thu Feb 5, 2026

$45.88 | -8.55%

Potential

CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91. The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11 2026. The price target is an average of many targets provided by ana

Tue Feb 3, 2026

$52.00 | +1.34%

Potential

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?. CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Feb 3, 2026

$52.00 | +1.34%

Earnings

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing. In the closing of the recent trading day CRISPR Therapeutics AG (CRSP) stood at $51.31 denoting a 2.7% move from the preceding trading day.

Mon Feb 2, 2026

$51.31 | +2.70%

Momentum

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought. Key PointsArk Invest bought shares of Joby Aviation Kodiak AI and CRISPR on Thursday.

Fri Jan 30, 2026

$49.96 | -6.35%

Activity

Potential

What Does the Market Think About CRISPR Therapeutics AG?. CRSP) short interest as a percent of float has fallen 3.73% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.Sho

Thu Jan 29, 2026

$53.35 | -0.63%

Momentum

Runners Also Watch

Close Price

Change

IBRX

ImmunityBio

5.95

-10.20%

CLDI

Calidi Biotherapeutics In

0.78

+4.25%

BNTX

BioNTech

105.87

+0.10%

BEAM

Beam Therapeutics In

27.92

+3.68%

AMGN

Amgen

369.19

+1.52%

FAQ About CRSP Stock Insights

What is CRSP current stock price?

What are CRSP stock strengths?

What is CRSP Risk Level?

What is CRSP market cap and volume?

What is CRSP current Stock IQ?

Should I buy CRSP stock right now?

Is CRSP a Strong Buy right now?

What does a 'Strong Buy' rating mean for CRSP?

What does a 'Strong Sell' rating mean for CRSP?

What factors influence CRSP's Stock IQ?

Explore our CRSP Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored CRSP Stock Strategies
Effective Risk Management

FIND US ON

Receive our CRSP Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

CRSP

CRISPR Therapeutics

Set Alerts

Current Price

$53.07

+$4.14 | +8.46%

52W High

$78.48

MKT CAP

$5.10B

52W Low

$30.06

VOL

$2.46M

P/E Ratio

N/A

AVG VOL

$1.77M

RSI

52.17

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

IBRX

ImmunityBio

5.95

-10.20%

CLDI

Calidi Biotherapeutics In

0.78

+4.25%

BNTX

BioNTech

105.87

+0.10%

BEAM

Beam Therapeutics In

27.92

+3.68%

AMGN

Amgen

369.19

+1.52%

CRSP Price Performance

$52.61 (+0.87%)

$50.77 (+4.53%)

$60.76 (-12.66%)

$43.45 (+22.14%)

1year

6month

3month

1month

CRSP Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

CRSP Analysts Opinion

CRSP Analysts opinion is negative and it remained unchanged from the past 3 months

CRSP Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

CRSP Street Sentiment

CRSP Street Sentiment is bullish and have positive views on the near-term outlook

CRSP Risk Level

CRSP has Fair risk level

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

CRSP Performance Sentiment

Sentiments overview associated with events and the stock performance.

72%

28%

Positive

Negative

13 out of 18
events present

5 out of 18
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$53.07

Resistance
Price

$45.88

Current Price Range

$60.80

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

6

0

Date

Action

Rating

Firm

Dec 31, 2025

Reiterate

Buy

Chardan

Dec 24, 2025

Reiterate

Buy

Needham

Dec 24, 2025

Reiterate

Outperform

Citizens

Nov 13, 2025

Reiterate

Buy

Citigroup

Oct 17, 2025

Reiterate

Buy

B of A Securities

CRSP Stock IQ

Login to unlock CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

CRSP Rewards

Earnings are forecast to grow

CRSP Rewards

Upgraded on attractively valued

CRSP Rewards

Trading below its fair value

CRSP Rewards

Outperform the market

CRSP Latest Analysis

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss). Key PointsCRISPR Therapeutics&rsquo. fourth quarter was relatively disappointing.

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

CRSP Posts Wider-Than-Expected Loss in Q4 Sales Miss Estimates. CRISPR Therapeutics posts a wider Q4 loss and revenues miss but Casgevy sales climb with label expansion plans and pipeline updates ahead.

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

Earnings

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens. CRSP) on Friday reported its fourth-quarter and highlighting continued clinical progress expanding uptake of Casgevy and momentum across its gene-editing and RNA-based pipeline.Casgevy the company’.s gene-editing and transfusion-dependent beta thalassemia generated $54 million in fourth-quarter revenue and $116 million for the full year.A total of 64 patients received infusions in 2025 including 30 during th

Fri Feb 13, 2026

$53.07 | +8.46%

Activity

CRISPR Therapeutics GAAP EPS of -$1.37 misses by $0.22 revenue of $0.86M misses by $3.16M.

Thu Feb 12, 2026

$48.93 | +1.26%

Earnings

Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline. CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30 Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that much of the pipeline remains undervalued and noted that the company could begin late-stage development for up to [….]

Thu Feb 5, 2026

$45.88 | -8.55%

Potential

CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91. The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11 2026. The price target is an average of many targets provided by ana

Tue Feb 3, 2026

$52.00 | +1.34%

Potential

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?. CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Feb 3, 2026

$52.00 | +1.34%

Earnings

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CRSP. We're here to help you make informed investment decisions today.

FIND US ON

Receive our CRSP Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CRSP Stock trends

CRSP Stock performance

CRSP Stock analysis

CRSP investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CRSP

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

CRSP Stock Analysis & IQ Rating | CRISPR Therapeutics

CRSP Stock IQ

CRSP Target Price

CRSP Analysts Opinion

CRSP Street Sentiment

CRSP Risk Level

CRSP Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our CRSP Stock insights

Receive our CRSP Daily Alerts

CRSP Street Sentiment

CRSP Risk Level

Key Price Levels

Latest Analyst Actions

Discover CRSP Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CRSP. We're here to help you make informed investment decisions today.

Receive our CRSP Daily Alerts

CRSP Alerts